5Cleland J,Coletta A,Clark A.Clinical trial update fromthe American College of Cardiology 2007:ALPHA,EV-EREST,FUSION,VALIDO,PARR-2,REMODEL,SPICE,COURAGE,COACH,REMADHE,pro-BNP forthe evaluation of dyspnoea and THIS-diet[J].EuropeanJournal of Heart Failure,2007,9(6-7):740-745.
6Jessup M,Abraham WT,Casey DE,et al.2009focesedupdate in corporated into the ACC/AHA 2005guidelinesfor the diagnosis and management of heart failure in a-dults[J].Am Coll Cardiol,2009,53(15):e1-e90.
8Granger CB,Mc Murray JJ,Yusuf S,et al.Effects of can-desartanin patients with chronic heart failure and reducedleft ventricular systolic function intolerat to angiotensinconverting enzyme inhibitors:the CHARM-Alternativetrial[J].Lancet,2003,362(9386):772-776.
7Pivac N,Rumboldt Z,Sardelic S.Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure.Int J Clin Pharmacol Res,1998,18(3):121-128.
8Macdonald PS,Hill J,Krum H.The impact of baseline HR and BP on the tolerability of carvedilol in the elderly:the COLA(Carvedilol Open Label Assessment)Ⅱ Study[J].Am J Cardiovasc Drugs,2006,6(6):401-405.
9Dobre D,van Veldhuisen DJ,Mordenti G,et al.Tolerability and dose-relatedeffects of nebivolol in elderly patients with heart failure:data from the Study ofthe Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Sen-iors with Heart Failure(SENIORS) trial[J].Am Heart J,2007,154(1):109-115.
10Willenheimer R,van Veldhuisen DJ,Silke B,et al.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study(CIBIS)Ⅲ[J].Circulation,2005,112(16):2426-2435.
4Wong M, Staszewasky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study [ J ]. J Am Coll Cardiol, 2002, 40 (5) : 970 -975.
5McMurray JJ, Ostergren J, Swedberg K, et al. Effects of cande- sartan in patients with chronic heart failure and reduced left-ven- tricular systolic function taking' angiotensin converting enzyme in- hibitors: the CHARM-Added trial [ J]'. Lancet, 2003, 362 (9386) :767 -771.
6Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guide- line update for the diagnosis and management of chronic heart failure in the adult [ J]. Circulation, 2005, 112 ( 12 ) : 154 - 235.
7Athanasopoulos LV, Dritsas A, Doll HA, et al. Comparative value of NYHA functional class and quality of life questionnaire scores in assessing heart failure [ J ]. J Cardiopulm Rehabil Prev, 2010, 30(2) : 101 - 105.
8The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asympto-matic patients with reduced left ventricular ejection fractions [ J]. N Engl J Med, 1992, 327(10) : 685 -691.
9Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesar- tan in patients with chronic heart failure and reduced left-ven- tricular systolic function intolerant to angiotensin-converting-en- zyme inhibitors: the CHARM-Alternative trial[J]. The Lancet, 2003, 362(9386) :772 -776.
10Tarantini G, Scrutinio D, Bmzzi P, et al. Metabolic trea- tment with L-camitine in acute anterior ST segment el- evation myocardial infarction. A randomized controlled controlled trial [J]. Cardiology, 2011, 106 (13) .. 215- 223.
